Search

Search Constraints

You searched for: Author/Creator Cobo, M.

Search Results

1. 3084 Phase III trial of afatinib vs erlotinib in patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8): EGFR molecular aberrations and survival outcomes. (September 2015)

2. 3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial. (September 2015)

3. 3112 Nintedanib in combination with cisplatin/gemcitabine as 1st-line therapy for advanced squamous non-small cell lung cancer. (September 2015)

4. EPIDEMIOLOGICAL STUDY ON THE GERIATRIC ASSESSMENT IN PATIENTS WITH HEMATOLOGICAL CANCER: AN UPDATE OF THE REGISTRY OF THE SPANISH GROUP ON HEMATOGERIATRICS. (November 2019)

5. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study. (January 2019)

7. Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders. (February 2017)

8. The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC. (February 2022)